[1] 张彦景, 宋晓坤.免疫检查点抑制剂致多系统免疫相关不良事件的诊疗思路[J].中国全科医学, 2023, 26(23):2930-2935.
[2] Wang S J, Dougan S K, Dougan M.Immune mechanisms of toxicity from checkpoint inhibitors[J].Trends Cancer, 2023, 9(7):543-553.
[3] Oren O, Yang H E, Molina R J, et al.Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors[J].Am J Cardiol, 2020, 125(12):1920-1926.
[4] Lyon A R, López-Fernández T, Couch L S, et al.2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA),the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)[J].Eur Heart J, 2022, 43(41):4229-4361.
[5] Schneider B J, Naidoo J, Santomasso B D, et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:ASCO Guideline Update[J].J Clin Oncol, 2021, 39(36):4073-4126.
[6] Chang L S, Barroso-Sousa R, Tolaney S M, et al.Endocrine toxicity of cancer immunotherapy targeting immune checkpoints[J]. Endocr Rev, 2019,40(1):17-65.
[7] Agrawal L, Bacal A, Jain S, et al.Immune checkpoint inhibitors and endocrine side effects, a narrative review[J]. Postgrad Med, 2020, 132(2):206-214.
[8] Johnson D B, Nebhan C A, Moslehi J J, et al.Immune-checkpoint inhibitors:long-term implications of toxicity[J]. Nat Rev Clin Oncol,2022,19(4):254-267.
[9] 刘天舒, 余一祎, 艾罗燕, 等.中国消化道肿瘤免疫治疗不良反应专家共识(2023年版)[J].肿瘤综合治疗电子杂志,2023,9(2):26-60.
[10] Lim S Y, Lee J H, Gide T N, et al.Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy[J].Clin Cancer Res, 2019, 25(5):1557-1563.
[11] Endo Y, Winarski K L, Sajib M S, et al.Atezolizumab induces necroptosis and contributes to hepatotoxicity of human hepatocytes[J].Int J Mol Sci, 2023,24(14):11694.
[12] Patrinely J R Jr, McGuigan B, Chandra S, et al.A multicenter characterization of hepatitis associated with immune checkpoint inhibitors[J].Oncoimmunology, 2021 ,10(1):1875639.
[13] Holstead R, Kartolo A, Baetz T.Emergency department utilization for patients receiving immune checkpoint inhibitors:a retrospective analysis of identification and outcomes for those presenting for immune-related adverse events[J].Curr Oncol, 2020, 28(1):52-59.
[14] 中国临床肿瘤学会(CSCO). 抗肿瘤药物相关肝损伤诊疗指南2024[M].北京:人民卫生出版社, 2024:1-113.
[15] Thompson J A, Schneider B J,Brahmer J, et al.NCCN Guidelines? insights:management of immunotherapy-related toxicities,version 2.2024[J].J Natl Compr Canc Netw, 2024,22(9):582-592.
[16] Liu X, Lu Y, Zhou W, et al.Chinese multidisciplinary expert consensus on immune checkpoint inhibitor-based combination therapy for hepatocellular carcinoma (2023 Edition)[J].Liver Cancer, 2024 ,13(4):355-375.
[17] Triantafyllou E, Gudd C L C, Possamai L A.Immune-mediated liver injury from checkpoint inhibitors:mechanisms,clinical characteristics and management[J].Nat Rev Gastroenterol Hepatol,2025,22(2):112-126.
[18] Quandt Z, Lucas A, Liang S I, et al.Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD:a prospective pan-tumor cohort study[J].J Immunother Cancer, 2025,13(5):e011545.
[19] Swanson L A, Hawa F, Fontana R J.Immune-mediated liver injury from checkpoint inhibitors:best practices in 2024[J].Clin Liver Dis (Hoboken), 2024, 23(1):e0191.
[20] Ali F S, Nguyen M H, Hernaez R, et al.AGA Clinical Practice Guideline on the prevention and treatment of hepatitis B virus reactivation in at-Risk individuals[J].Gastroenterology, 2025,168(2):267-284.
[21] Yu Y, Wang S, Su N, et al.Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer[J]. Front Oncol, 2022,12:906824.
[22] Burke K P, Patterson D G, Liang D, et al.Immune checkpoint receptors in autoimmunity[J]. Curr Opin Immunol, 2023,80:102283.
[23] Chennamadhavuni A, Abushahin L, Jin N, et al.Risk factors and biomarkers for immune-related adverse events:a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors[J].Front Immunol, 2022,13:779691. |
